US trade agency extends deadline of Novo Nordisk's historic acquisition

Novo Nordisk has stumbled right before the finish line of the historic acquisition of US-based biotech firm Dicerna. Novo Nordisk has been awarded additional time to get back up by the US Federal Trade Commission (FTC).

Photo: Stine Tidsvilde

While shareholders in Dicerna are suing, claiming they received misleading information pertaining to the acquisition of the firm, would-be buyer Novo Nordisk has run into other issues with the US Federal Trade Commission (FTC).

In connection with the deal between Dicerna and Novo Nordisk, the latter company has sent in relevant documents to the agency. This is required in the US under the Hart-Scott-Rodino Antitrust Improvements Act.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs